drugset
drugset / Trial / NCT04497662

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy Subjects

NCT04497662 ↗

Phase 1 Completed 52 enrolled Kiniksa Pharmaceuticals, Ltd.
RandomizedSequentialTriple-blindOther

Summary

Phase 1, randomized, double-blind, placebo-controlled first-in-human study to investigate the safety, tolerability, PK and PD properties of single ascending intravenous (IV) and subcutaneous (SC) doses of KPL-404 in healthy subjects

Timeline

Start
2019-10-22
Primary completion
2021-01-21
Completion
2021-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Abiprubart Monoclonal antibody — Intravenous

Indications

No indication recorded.